Amicus Therapeutics, Inc. (FOLD) Social Stream
Amicus Therapeutics Inc (FOLD) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering FOLD.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
---|---|---|---|---|---|---|
2021-11-10 | 11 | $29 | $12 | $18.333 | $9.47 | 93.59% |
2021-11-15 | 10 | $29 | $12 | $18.444 | $9.47 | 94.76% |
2021-11-23 | 10 | $29 | $12 | $18.555 | $9.47 | 95.93% |
2022-01-13 | 9 | $29 | $12 | $17.375 | $9.47 | 83.47% |
2022-01-17 | 9 | $29 | $15 | $17.875 | $9.47 | 88.75% |
2022-01-26 | 9 | $29 | $15 | $17.5 | $9.47 | 84.79% |
2022-02-25 | 9 | $29 | $14 | $17 | $9.47 | 79.51% |
2022-02-28 | 9 | $20 | $14 | $15.5 | $9.47 | 63.67% |
The Trend in the Analyst Price Target
FOLD's average price target has moved down $1.5 over the prior 26 weeks.
FOLD reports an average of 71.04% for its upside potential over the past 47 weeks.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
---|---|---|---|---|---|---|
2021-04-03 | 10 | 29 | 12.5 | 17.79 | 10.06 | 76.84% |
2021-07-10 | 12 | 29 | 12.0 | 16.88 | 9.62 | 75.47% |
2021-09-04 | 13 | 29 | 13.0 | 16.90 | 11.63 | 45.31% |
2021-09-11 | 13 | 29 | 13.0 | 16.90 | 10.93 | 54.62% |
2021-11-23 | 10 | 29 | 12.0 | 17.50 | 11.33 | 54.46% |
FOLD Broker Recommendations Summary
Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
---|---|---|---|---|---|---|
1.22 | 8 | 0 | 1 | 0 | 0 | 9 |
The Trend in the Broker Recommendations
FOLD's average broker recommendation rating improved by 1.4 over the prior 31 weeks.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for FOLD as an investment opportunity.
- In the context of all US stocks, Amicus Therapeutics Inc's variance in analysts' estimates is lower than -849.89% of them.
- To contextualize these metrics, consider that out of all US stocks, Amicus Therapeutics Inc's average analyst price target is higher than 213.89% of them.
- In terms of how Amicus Therapeutics Inc fares relative to Pharmaceutical Products stocks, note that its number of analysts covering the stock is higher than 867.45% of that group.
- In the context of stocks in the mid market cap category, Amicus Therapeutics Inc's upside potential (average analyst target price relative to current price) is higher than 831.93% of them.
In the Pharmaceutical Products industry, FGEN, EVO, and ESPR are the three stocks most similar to Amicus Therapeutics Inc regarding the price target and analyst recommendation information presented here.
Is FOLD a Buy, Hold or Sell? See the POWR Ratings now!